Mirati Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The company focuses on developing a pipeline of oncology products to treat genetic and epigenetic drivers of cancer in selected subsets of cancer patients .Its product candidates include glesatinib, sitravatinib and mocetinostat. The company was founded on December 13, 1995 and is headquartered in San Diego, CA.
